Overview
New Possibilities for Maintenance Therapy in AML
AML Case Challenge
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
A new maintenance option is available for AML, but are you proficient in identifying eligible patients? Dr. DiNardo and Dr. Roboz present 3 cases with particular attention to and discussion of risks of relapse in AML, the role of maintenance therapy, and shared decision-making to engage patients in discussions surrounding maintenance therapy.
This activity is intended for hematologists/oncologists and hematology nurse practitioners, physician assistants and other members of the multidisciplinary care team who treat patients with AML
The role of maintenance treatment in AML care has significantly transformed in recent times; as a result, patients now have more options and less relapse should occur. However, due to the volume and complexity of information that has recently emerged, clinicians may be challenged to keep abreast of the latest developments surrounding maintenance care in AML. To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the latest developments that could significantly impact patient outcomes.
Upon completion of this activity, participants will be able to:
• Discuss predictive factors that contribute to patient relapse in acute myeloid leukemia (AML).
• Analyze recent clinical trial data of new and emerging therapies for AML in the maintenance setting.
• Formulate collaborative strategies and shared decision-making (SDM) practices to ensure patient engagement in treatment decisions regarding AML care.
• Discuss predictive factors that contribute to patient relapse in acute myeloid leukemia (AML).
• Analyze recent clinical trial data of new and emerging therapies for AML in the maintenance setting.
• Formulate collaborative strategies and shared decision-making (SDM) practices to ensure patient engagement in treatment decisions regarding AML care.
Sponsored by PennState College of Medicine and the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Bristol Myers Squibb.
Courtney DiNardo, MD, MSCE
Associate Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Associate Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Gail J. Roboz, MD
Director, Clinical and Translational Leukemia Programs
Professor of Medicine
Weill Cornell Medical College
The New York Presbyterian Hospital
New York, NY
Penn State College of Medicine requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
The following financial relationships have been provided:
Courtney DiNardo, MD, MSCE
Honorarium recipient: Abbvie/Genentech, Astellas, Celgene/BMS, Foghom, Notable Labs, ImmuniOnc, Servier, Novartis, Takeda
Gail J. Roboz, MD
Consultancy or Advisory Board or Data and Safety Monitoring Committee: Actinium, AbbVie, Agios, Amgen, Astellas, AstraZeneca, Bristol Myers Squibb, Blueprint Medicines, Bluebird Bio, Celgene, Glaxo SmithKline, Janssen, Jasper Therapeutics, Jazz, MEI Pharma (IDMC Chair), Mesoblast, Novartis, Pfizer, Syndax, Takeda(IRC Chair)
Research Support: Janssen
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Therapies not approved in the maintenance setting
ACHL, Penn State College of Medicine staff and faculty involved in the development, and review of this activity have disclosed no relevant financial relationships.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 80% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Penn State College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
